Tetraphase Pharmaceuticals (TTPH) Posts Quarterly Earnings Results, Meets Expectations
Tetraphase Pharmaceuticals (NASDAQ:TTPH) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40), Morningstar.com reports. Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%.
TTPH opened at $1.30 on Friday. Tetraphase Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $4.49. The company has a market capitalization of $66.50 million, a P/E ratio of -0.49 and a beta of 2.99.
Several analysts recently issued reports on TTPH shares. Robert W. Baird reissued a “buy” rating and issued a $3.00 price target on shares of Tetraphase Pharmaceuticals in a report on Monday, January 7th. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. B. Riley started coverage on Tetraphase Pharmaceuticals in a report on Friday, January 4th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, Piper Jaffray Companies reissued an “overweight” rating and issued a $4.00 price target (down previously from $6.00) on shares of Tetraphase Pharmaceuticals in a report on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $4.54.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Further Reading: What is a blue-chip stock?
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.